ATE410201T1 - Neue verfahren zur behandlung und vorbeugung von schmerzmittel inhibitoren der stressaktivierten proteinkinase - Google Patents

Neue verfahren zur behandlung und vorbeugung von schmerzmittel inhibitoren der stressaktivierten proteinkinase

Info

Publication number
ATE410201T1
ATE410201T1 AT02769765T AT02769765T ATE410201T1 AT E410201 T1 ATE410201 T1 AT E410201T1 AT 02769765 T AT02769765 T AT 02769765T AT 02769765 T AT02769765 T AT 02769765T AT E410201 T1 ATE410201 T1 AT E410201T1
Authority
AT
Austria
Prior art keywords
prevention
stress
treatment
protein kinase
kinase inhibitors
Prior art date
Application number
AT02769765T
Other languages
English (en)
Inventor
Lisa Aimone
Robert Hudkins
Mathew Miller
Original Assignee
Cephalon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cephalon Inc filed Critical Cephalon Inc
Application granted granted Critical
Publication of ATE410201T1 publication Critical patent/ATE410201T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AT02769765T 2001-05-16 2002-05-16 Neue verfahren zur behandlung und vorbeugung von schmerzmittel inhibitoren der stressaktivierten proteinkinase ATE410201T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29122701P 2001-05-16 2001-05-16
US10/146,680 US7018999B2 (en) 2001-05-16 2002-05-15 Methods for the treatment and prevention of pain

Publications (1)

Publication Number Publication Date
ATE410201T1 true ATE410201T1 (de) 2008-10-15

Family

ID=26844179

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02769765T ATE410201T1 (de) 2001-05-16 2002-05-16 Neue verfahren zur behandlung und vorbeugung von schmerzmittel inhibitoren der stressaktivierten proteinkinase

Country Status (13)

Country Link
US (1) US7018999B2 (de)
EP (1) EP1389100B1 (de)
JP (1) JP2004534751A (de)
AR (1) AR035971A1 (de)
AT (1) ATE410201T1 (de)
AU (1) AU2002342715A1 (de)
CA (1) CA2447091C (de)
DE (1) DE60229233D1 (de)
DK (1) DK1389100T3 (de)
ES (1) ES2314101T3 (de)
HK (1) HK1062806A1 (de)
MX (1) MXPA03010451A (de)
WO (1) WO2002092065A2 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7241779B2 (en) 2003-12-23 2007-07-10 Cephalon, Inc. Fused pyrrolocarbazoles
US7169802B2 (en) 2003-12-23 2007-01-30 Cephalon, Inc. Fused pyrrolocarbazoles
CN104016992B (zh) 2008-11-19 2017-04-12 赛福伦公司 吲唑并[5,4‑a]吡咯并[3,4‑c]咔唑化合物的形式

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1381031A (en) 1920-01-19 1921-06-07 Thompson James Dumping-wagon
EP0303697B1 (de) 1987-03-09 1997-10-01 Kyowa Hakko Kogyo Co., Ltd. Derivate des physiologisch aktiven mittels k-252
US5093330A (en) 1987-06-15 1992-03-03 Ciba-Geigy Corporation Staurosporine derivatives substituted at methylamino nitrogen
JPH07113027B2 (ja) 1987-12-24 1995-12-06 協和醗酵工業株式会社 K−252誘導体
WO1993008809A1 (en) 1991-11-08 1993-05-13 The University Of Southern California Compositions containing k-252 compounds for potentiation of neurotrophin activity
US5621101A (en) 1992-07-24 1997-04-15 Cephalon, Inc. Protein kinase inhibitors for treatment of neurological disorders
US5756494A (en) 1992-07-24 1998-05-26 Cephalon, Inc. Protein kinase inhibitors for treatment of neurological disorders
CA2163904C (en) 1993-05-28 2000-01-25 Craig A. Dionne Use of indolocarbazole derivatives to treat a pathological condition of the prostate
US6514745B1 (en) 1993-07-19 2003-02-04 The Regents Of The University Of California Oncoprotein protein kinase
US5534426A (en) 1993-07-19 1996-07-09 The Regents Of The University Of California Oncoprotein protein kinase
US5468872A (en) 1993-09-16 1995-11-21 Cephalon, Inc. K-252a functional derivatives potentiate neurotrophin-3 for the treatment of neurological disorders
US5599808A (en) 1994-02-18 1997-02-04 Cephalon, Inc. Aqueous indolocarbazole solutions
US5594009A (en) 1994-10-14 1997-01-14 Cephalon, Inc. Fused pyrrolocarbazoles
US5705511A (en) 1994-10-14 1998-01-06 Cephalon, Inc. Fused pyrrolocarbazoles
US6046208A (en) 1996-01-11 2000-04-04 Smithkline Beecham Corporation Substituted imidazole compounds
US5616724A (en) 1996-02-21 1997-04-01 Cephalon, Inc. Fused pyrrolo[2,3-c]carbazole-6-ones
UA67725C2 (en) 1996-06-03 2004-07-15 Cephalon Inc K-252a derivatives and a method for improvement of functioning and cell survival enhancement
DE69715862T2 (de) 1996-06-25 2003-04-10 Cephalon Inc Verwendung eines k-252a derivats zur behandlung von periphärer oder zentraler nervenerkrankungen und übermässiger cytokinbildung
DK1044203T3 (da) 1997-12-31 2003-07-14 Cephalon Inc 3'-epimere K-252a-derivater
WO1999053927A1 (en) 1998-04-17 1999-10-28 Trustees Of Tufts College Methods for treating and preventing insulin resistance and related disorders
US6811992B1 (en) 1998-05-14 2004-11-02 Ya Fang Liu Method for identifying MLK inhibitors for the treatment of neurological conditions
GB9811624D0 (en) 1998-05-29 1998-07-29 Merck Sharp & Dohme Therapeutic use
US6127401A (en) 1998-06-05 2000-10-03 Cephalon, Inc. Bridged indenopyrrolocarbazoles
US6207687B1 (en) 1998-07-31 2001-03-27 Merck & Co., Inc. Substituted imidazoles having cytokine inhibitory activity
EA200500934A1 (ru) 1998-08-26 2006-04-28 Сефалон, Инк. Соединения, модулирующие активность киназного белка множественных линий, и способы лечения нейродегенеративных и воспалительных заболеваний
KR20010101266A (ko) 1998-12-17 2001-11-14 프리돌린 클라우스너, 롤란드 비. 보레르 Jnk 단백질 키나제의 억제제로서의 4-아릴옥신돌
TR200101747T2 (tr) 1998-12-17 2001-11-21 F.Hoffmann-La Roche Ag 4- ve 5-alkinil oksindoller ve 4- ve 5-alkeniloksindoller.
CN1158283C (zh) 1998-12-17 2004-07-21 霍夫曼-拉罗奇有限公司 作为蛋白激酶抑制剂的4-和5-吡嗪基羟吲哚
US6841567B1 (en) 1999-02-12 2005-01-11 Cephalon, Inc. Cyclic substituted fused pyrrolocarbazoles and isoindolones
ATE425142T1 (de) 1999-04-23 2009-03-15 Vertex Pharma Inhibitoren von c-jun n-terminal kinasen (jnk)
AU5316900A (en) 1999-06-03 2000-12-28 Vertex Pharmaceuticals Incorporated Inhibitors of c-jun n-terminal kinases (jnk)
WO2001001986A1 (en) 1999-07-02 2001-01-11 Lipton Stuart A Method of reducing neuronal injury or apoptosis
HUP0202319A3 (en) 1999-07-16 2004-12-28 Warner Lambert Co Use of mek inhibitors for the preparation of pharmaceutical compositions treating chronic pain
AU6909600A (en) 1999-08-13 2001-03-13 Vertex Pharmaceuticals Incorporated Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases
EP1218347A1 (de) 1999-08-19 2002-07-03 Signal Pharmaceuticals, Inc. Pyrazoloanthrone und deren derivate als jnk inhibitoren und ihre zusammensetzungen
US6399780B1 (en) 1999-08-20 2002-06-04 Cephalon, Inc. Isomeric fused pyrrolocarbazoles and isoindolones
CA2410475A1 (en) 2000-06-01 2001-12-06 Merck & Co., Inc. Use of (di-substituted-phenyl)-pyrimidinyl-imidazole derivatives as jnk-inhibitors
WO2002038035A2 (en) 2000-11-08 2002-05-16 The General Hospital Corporation Methods for inhibiting pain
ES2307667T3 (es) 2000-12-05 2008-12-01 Vertex Pharmaceuticals Incorporated Inhibidires de quinasas terminales c-jun(jnk) y otras proteinas quinasas.

Also Published As

Publication number Publication date
ES2314101T3 (es) 2009-03-16
HK1062806A1 (en) 2004-11-26
MXPA03010451A (es) 2004-05-05
DK1389100T3 (da) 2008-12-08
US20030087899A1 (en) 2003-05-08
JP2004534751A (ja) 2004-11-18
EP1389100B1 (de) 2008-10-08
WO2002092065A2 (en) 2002-11-21
EP1389100A2 (de) 2004-02-18
AR035971A1 (es) 2004-07-28
AU2002342715A1 (en) 2002-11-25
US7018999B2 (en) 2006-03-28
CA2447091C (en) 2012-03-27
WO2002092065A3 (en) 2003-07-31
CA2447091A1 (en) 2002-11-21
DE60229233D1 (de) 2008-11-20

Similar Documents

Publication Publication Date Title
DE60143061D1 (de) Verwendung von Botulinum Toxin zur Behandlung von Gelenkschmerzen
DE60105295D1 (de) Chinazolinderivate zur behandlung von tumoren
ATE527022T1 (de) Verwendung von cyclooxygenase-2-inhibitoren zur behandlung und vorbeugung von tumoren, von tumor- abhängigen erkrankungen und kachexie
ATE247117T1 (de) Pyrazolopyrimidinone cgmp pde5 inhibitoren zur behandlung von sexualfunktionsstörungen
DE60335293D1 (de) Pyrrolopyridazin-verbindungen und verwendungsverfahren dafür zur behandlung von proliferativen erkrankungen
DE60227095D1 (de) Zusammensetzungen und verfahren zur behandlung von abgebundenem gips
ATE286028T1 (de) Aminopyrazolderivate zur behandlung von übergewicht und anderen gesundheitsstörungen
DE60124302D1 (de) Thiazolderivate zur behandlung von ppar-lierte krankheiten
DE60114580D1 (de) Verwendung von cyanochinolinen zur behandlung oder inhibierung von dickdarmpolypen
DE60223715D1 (de) Glyt1 transporter inhibitoren und deren anwendung in der behandlung von neurologischen und neuropsychiatischen krankheiten
ATE291438T1 (de) Pharmazeutische zusammensetzung zur behandlung von akutem schmerz, chronischem schmerz und/oder neuropathischem schmerz und migräne
ATE417602T1 (de) Mittel zur behandlung von erkrankungen der speiseröhre
DE60221798D1 (de) Kombinationen von gallensäuresequestriermitteln und hemmern der sterolabsorption zur behandlung von kardiovaskulären indikationen
ATE413385T1 (de) Zur behandlung von schmerzen geeignete therapeutische mittel
DE60224163D1 (de) Kombinationen von ezetimibe und aspirin zur behandlung von kardiovaskulären erkrankungen
DE60214542D1 (de) Verwendung von cox2 inhibitoren zur behandlung von schizophrenia und des ticks
DE60208186D1 (de) Chinazolin- und chinazolinähnliche verbindungen zur behandlung von integrinvermittelten erkrankungen
ATE296628T1 (de) Integrinhemmer zur behandlung von augenkrankheiten
DE60134009D1 (de) Verwendung von il-18 inhibitoren zur behandlung und/oder prävention von atherosklerose
ATE369130T1 (de) Carbamatverbindungen zur vorbeugung und behandlung von bewegungsstörungen
DE60238765D1 (de) Carbamatverbindungen zur behandlung von schmerz
DE50114605D1 (de) No-thien-2-yl-essigsaure-derivate und ihre verwendung zur behandlung von migraine bzw. schmerz
DE60224004D1 (de) Verwendung von il-18 hemmern zur behandlung und/oder prävention von herzkrankheiten
ATE312104T1 (de) Verbindungen zur behandlung von beeinträchtigten fundischen entspannung
DE60223707D1 (de) Calcium-l-threonat zur behandlung von knochenfrakturen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties